A new “magic mushroom” drug could treat depression without psychedelic hallucinations
Scientists are exploring a new way to harness the medical promise of psychedelic compounds without the mind-bending side effects. Researchers created modified versions of psilocin — the active form of psilocybin from “magic mushrooms” — that still target key serotonin pathways linked to depression and other brain disorders but appear to cause far fewer psychedelic-like effects.
External link. We are not responsible for the content.
Read more ↗More From ScienceDaily Psychedelics
Is cannabis safe after 65? Stanford experts reveal 5 risks older adults should know
Cannabis use among older adults is rising fast, but today’s marijuana is far more potent than many people realize — a...
New psychedelic-like drugs could treat depression without making you trip
UC Davis researchers created brand-new psychedelic-like compounds by shining UV light on amino acid-based molecules. ...
Scientists say 7 days of meditation can rewire your brain
A single week of intensive meditation and mind-body practices led to measurable changes across the brain and body. Re...
Latest News
Out of This World: Why AI Belongs Beside the Therapist
Safar founder Sabba Nazhand watched the mental health system fail his mother, then himself. He argues AI's place is b...
An Amanita mushroom poisoning outbreak in California; A case report testing psilocybin for advanced Alzheimer’s disease
Plus: Scientists assess risk of psychedelic-induced mania; and the close of this season’s psychedelic legislation push
When Do Psychedelics Go Too Far?
Welcome to The Psychedelic Blog.
Do Psychedelics Actually Improve Athletic Performance?
Athletes say they feel stronger, calmer, and faster. Does the data back this up? [...] Read More... The post Do Psych...
Shroomski Melt
Shroomski Magazine drops their latest issue at their annual Summer Melt with cover art done by the one and only, Luke...
Psychedelic Policy Briefing: June 11, 2026
Six states are moving fast on psychedelic policy in 2026: Michigan fights over ibogaine research funding, Colorado si...